The use of derivatives of natural and synthetic origin has gained attention because of their
therapeutic effects against human diseases. Coumarins are one of the most common …

Mathematical modelling approaches have become increasingly abundant in cancer
research. The complexity of cancer is well suited to quantitative approaches as it provides …

Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) was
first recognized in 2004 as a distinct, clinically relevant molecular subset of lung cancer. The …

Increasing knowledge of intertumor heterogeneity, intratumor heterogeneity, and cancer
evolution has improved the understanding of anticancer treatment resistance. A better …

A new ecologically inspired paradigm in cancer treatment known as “adaptive therapy”
capitalizes on competitive interactions between drug-sensitive and drug-resistant subclones …

Non–small cell lung cancers (NSCLCs) that harbor mutations within the epidermal growth
factor receptor (EGFR) gene are sensitive to the tyrosine kinase inhibitors (TKIs) gefitinib …

Acquired drug resistance is a major limitation for the successful treatment of cancer.
Resistance can emerge due to a variety of reasons including host environmental factors as …

Tumor evolution presents a formidable obstacle that currently prevents the development of
truly curative treatments for cancer. In this perspective, we advocate for the hypothesis that …

Drug resistance has profoundly limited the success of cancer treatment, driving relapse,
metastasis, and mortality. Nearly all anticancer drugs and even novel immunotherapies …

Unless diagnosed early, many adult cancers remain incurable diseases. This is despite an
intense global research effort to develop effective anticancer therapies, calling into question …